Hypereosinophilic Syndrome and Molecularly Targeted Therapy

Seminars in Hematology

Volumn 44, Issue SUPPL. 2, 2007, Pages S4-

  Martinelli, Giovanni ^a   Rondoni, Michela ^a   Ottaviani, Emanuela ^a   Paolini, Stefania ^a   Baccarani, Michele ^a  

^a Institute of Hematology and Medical Oncology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BUSULFAN; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; CYTOTOXIC AGENT; ETOPOSIDE; HYDROXYUREA; IMATINIB; INTERLEUKIN 5 ANTIBODY; MEPOLIZUMAB; METHOTREXATE; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PREDNISONE; PROTEIN TYROSINE KINASE; SCH 55700; STEM CELL FACTOR; TIOGUANINE; UNCLASSIFIED DRUG; VINCRISTINE;

ANEMIA; ARTICLE; BONE MARROW TOXICITY; CARDIOVASCULAR DISEASE; CATARACT; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CYTOLOGY; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHIL COUNT; EOSINOPHILIA; FIP1L1 GENE; FUSION GENE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; GENE; GENETIC MARKER; GENOTYPE; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPEREOSINOPHILIC SYNDROME; IDIOPATHIC DISEASE; INCIDENCE; KIF5B GENE; LOW DRUG DOSE; LUNG COMPLICATION; LUNG FIBROSIS; LYMPHATIC LEUKEMIA; MOLECULAR BIOLOGY; MONOTHERAPY; MOON FACE; MULTIPLE ORGAN FAILURE; MYELODYSPLASIA; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; MYOPATHY; NEPHROTOXICITY; NEUROLOGICAL COMPLICATION; NONHUMAN; OSTEOPOROSIS; PATHOGENICITY; PATHOPHYSIOLOGY; PDGFRA GENE; PRIORITY JOURNAL; PROGNOSIS; SINGLE DRUG DOSE; SKIN DISEASE; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

EID: 34047129599     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2007.02.002     Document Type: Article

References (103)

1. Fauci A.S., Harley J.B., Roberts W.C., Ferrans V.J., Gralnick H.R., and Bjornson B.H. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 97 (1982) 78-92
2. Chusid M.J., Dale D.C., West B.C., and Wolff S.M. The hypereosinophilic syndrome: Analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54 (1975) 1-27
3. Weller P.F., and Bubley G.J. The idiopathic hypereosinophilic syndrome. Blood 83 (1994) 2759-2779
4. Lefebvre C., Bletry O., Degoulet P., Guillevin L., Bentata-Pessayre M., Le Thi Huong D., et al. [Prognostic factors of hypereosinophilic syndrome. Study of 40 cases]. Ann Med Interne (Paris) 140 (1989) 253-257
5. Roufosse F., Cogan E., and Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med 54 (2003) 169-184
6. Cools J. The hypereosinophilic syndrome: Idiopathic or not, that is the question. Haematologica 90 (2005) 582-584
7. Wilkins H.J., Crane M.M., Copeland K., and Williams W.V. Hypereosinophilic syndrome: An update. Am J Hematol 80 (2005) 148-157
8. Klion A.D., Noel P., Akin C., Law M.A., Gilliland D.G., Cools J., et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 101 (2003) 4660-4666
9. Vandenberghe P., Wlodarska I., Michaux L., Zachee P., Boogaerts M., Vanstraelen D., et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 18 (2004) 734-742
10. Gotlib J. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Acta Haematol 114 (2005) 7-25
11. Bain B.J. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome. Br J Haematol 95 (1996) 2-9
12. Karnak D., Kayacan O., Beder S., and Delibalta M. Hypereosinophilic syndrome with pulmonary and cardiac involvement in a patient with asthma. CMAJ 168 (2003) 172-175
13. Spry C.J., Davies J., Tai P.C., Olsen E.G., Oakley C.M., and Goodwin J.F. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med 52 (1983) 1-22
14. Assa'ad A.H., Spicer R.L., Nelson D.P., Zimmermann N., and Rothenberg M.E. Hypereosinophilic syndromes. Chem Immunol 76 (2000) 208-229
15. Bain B.J. Hypereosinophilia. Curr Opin Hematol 7 (2000) 21-25
16. Bain B.J. Eosinophilic leukemia and idiopathic hypereosinophilic syndrome are mutually exclusive diagnoses. Blood 104 (2004) 3836 author reply 3836-3837
17. Sanderson C.J. Interleukin-5, eosinophils, and disease. Blood 79 (1992) 3101-3109
18. Roufosse F., Bartholomé E., Schandene L., Goldman M., and Cogan E. The idiopathic hypereosinophilic syndrome: Clinical presentation, pathogenesis and therapeutic strategies. Drugs Today (Barc) 34 (1998) 361-373
19. Simon D., Braathen L.R., and Simon H.U. Anti-interleukin-5 antibody therapy in eosinophilic diseases. Pathobiology 72 (2005) 287-292
20. Weller P.F., Monahan-Earley R.A., Dvorak H.F., and Dvorak A.M. Cytoplasmic lipid bodies of human eosinophils. Subcellular isolation and analysis of arachidonate incorporation. Am J Pathol 138 (1991) 141-148
21. Gleich G.J. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 105 (2000) 651-663
22. Gotlib J., Cools J., Malone III J.M., Schrier S.L., Gilliland D.G., and Coutre S.E. The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: Implications for diagnosis, classification, and management. Blood 103 (2004) 2879-2891
23. Ascione L., De Michele M., Accadia M., Spadaro P., Rumolo S., and Tuccillo B. Reversal of cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome using a tyrosine kinase inhibitor. Eur J Echocardiogr 5 (2004) 386-390
24. Stone R.M., Gilliland D.G., and Klion A.D. Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome. Semin Oncol 31 suppl 6 (2004) 12-17
25. Parrillo J.E., Fauci A.S., and Wolff S.M. Therapy of the hypereosinophilic syndrome. Ann Intern Med 89 (1978) 167-172
26. Moore P.M., Harley J.B., and Fauci A.S. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med 102 (1985) 109-114
27. Epstein D.M., Taormina V., Gefter W.B., and Miller W.T. The hypereosinophilic syndrome. Radiology 140 (1981) 59-62
28. Hill R., Wang N.S., and Berry G. Hypereosinophilic syndrome with pulmonary vascular involvement. Angiology 35 (1984) 238-244
29. Parrillo J.E., Borer J.S., Henry W.L., Wolff S.M., and Fauci A.S. The cardiovascular manifestations of the hypereosinophilic syndrome. Prospective study of 26 patients, with review of the literature. Am J Med 67 (1979) 572-582
30. Leiferman K.M., O'Duffy J.D., Perry H.O., Greipp P.R., Giuliani E.R., and Gleich G.J. Recurrent incapacitating mucosal ulcerations. A prodrome of the hypereosinophilic syndrome. JAMA 247 (1982) 1018-1020
31. Klion A.D., Bochner B.S., Gleich G.J., Nutman T.B., Rothenberg M.E., Simon H.U., et al. Approaches to the treatment of hypereosinophilic syndromes: A workshop summary report. J Allergy Clin Immunol 117 (2006) 1292-1302
32. Klion A.D. Recent advances in the diagnosis and treatment of hypereosinophilic syndromes. Hematology (Am Soc Hematol Educ Program) (2005) 209-214
33. Gotlib J., Cross N.C., and Gilliland D.G. Eosinophilic disorders: Molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol 19 (2006) 535-569
34. Butterfield J.H. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol 114 (2005) 26-40
35. Tefferi A., Patnaik M.M., and Pardanani A. Eosinophilia: Secondary, clonal and idiopathic. Br J Haematol 133 (2006) 468-492
36. Gleich G.J., and Leiferman K.M. The hypereosinophilic syndromes: Still more heterogeneity. Curr Opin Immunol 17 (2005) 679-684
37. Sutton S.A., Assa'ad A.H., and Rothenberg M.E. Anti-IL-5 and hypereosinophilic syndromes. Clin Immunol 115 (2005) 51-60
38. Malbrain M.L., Van den Bergh H., and Zachee P. Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: Complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. Br J Haematol 92 (1996) 176-183
39. Yamada O., Kitahara K., Imamura K., Ozasa H., Okada M., and Mizoguchi H. Clinical and cytogenetic remission induced by interferon-alpha in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation. Am J Hematol 58 (1998) 137-141
40. Luciano L., Catalano L., Sarrantonio C., Guerriero A., Califano C., and Rotoli B. αIFN-induced hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(1;5). Haematologica 84 (1999) 651-653
41. Yoon T.Y., Ahn G.B., and Chang S.H. Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: Report of a case and literature review. J Dermatol 27 (2000) 110-115
42. Baratta L., Afeltra A., Delfino M., De Castro S., Giorgino F., and Rossi-Fanelli F. Favorable response to high-dose interferon-alpha in idiopathic hypereosinophilic syndrome with restrictive cardiomyopathy-Case report and literature review. Angiology 53 (2002) 465-470
43. Zabel P., and Schlaak M. Cyclosporin for hypereosinophilic syndrome. Ann Hematol 62 (1991) 230-231
44. Klion A.D., Law M.A., Noel P., Kim Y.J., Haverty T.P., and Nutman T.B. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 103 (2004) 2939-2941
45. Garrett J.K., Jameson S.C., Thomson B., Collins M.H., Wagoner L.E., Freese D.K., et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113 (2004) 115-119
46. Anastasiadou E., and Schwaller J. Role of constitutively activated protein tyrosine kinases in malignant myeloproliferative disorders: An update. Curr Opin Hematol 10 (2003) 40-48
47. Hannah A.L. Kinases as drug discovery targets in hematologic malignancies. Curr Mol Med 5 (2005) 625-642
48. Krause D.S., and Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 353 (2005) 172-187
49. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Druker B.J., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56 (1996) 100-104
50. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295 (2000) 139-145
51. Heinrich M.C., Rubin B.P., Longley B.J., and Fletcher J.A. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 33 (2002) 484-495
52. Dewar A.L., Cambareri A.C., Zannettino A.C., Miller B.L., Doherty K.V., Hughes T.P., et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 105 (2005) 3127-3132
53. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (1996) 561-566
54. Okuda K., Weisberg E., Gilliland D.G., and Griffin J.D. ARG tyrosine kinase activity is inhibited by STI571. Blood 97 (2001) 2440-2448
55. Peng B., Lloyd P., and Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44 (2005) 879-894
56. van Oosterom A.T., Judson I., Verweij J., Stroobants S., Donato di Paola E., Dimitrijevic S., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358 (2001) 1421-1423
57. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 472-480
58. van Oosterom A.T., Judson I.R., Verweij J., Stroobants S., Dumez H., Donato di Paola E., et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: A report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38 suppl 5 (2002) S83-S87
59. Heinrich M.C., Corless C.L., Duensing A., McGreevey L., Chen C.J., Joseph N., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 (2003) 708-710
60. Debiec-Rychter M., Dumez H., Judson I., Wasag B., Verweij J., Brown M., et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40 (2004) 689-695
61. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 (2003) 1201-1214
62. La Starza R., Specchia G., Cuneo A., Beacci D., Nozzoli C., Luciano L., et al. The hypereosinophilic syndrome: Fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica 90 (2005) 596-601
63. Pardanani A., Brockman S.R., Paternoster S.F., Flynn H.C., Ketterling R.P., Lasho T.L., et al. FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 104 (2004) 3038-3045
64. Roche-Lestienne C., Lepers S., Soenen-Cornu V., Kahn J.E., Lai J.L., Hachulla E., et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 19 (2005) 792-798
65. Pardanani A., Ketterling R.P., Brockman S.R., Flynn H.C., Paternoster S.F., Shearer B.M., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102 (2003) 3093-3096
66. Robyn J., Lemery S., McCoy J.P., Kubofcik J., Kim Y.J., Pack S., et al. Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Br J Haematol 132 (2006) 286-292
67. Yamada Y., Rothenberg M.E., Lee A.W., Akei H.S., Brandt E.B., Williams D.A., et al. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Blood 107 (2006) 4071-4079
68. Klion A.D., Robyn J., Akin C., Noel P., Brown M., Law M., et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103 (2004) 473-478
69. Martinelli G., Cilloni D., Rondoni M., Messa F., Ottaviani E., Gottardi E., et al. Imatinib mesylate can induce molecular complete remission in idiopathic hypereosinophilic syndrome (HES). A phase II multicentric Italian clinical trial. Blood 106 (2005) 113a (abstr 375)
70. Chung K.F., Hew M., Score J., Jones A.V., Reiter A., Cross N.C., et al. Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity. Eur Respir J 27 (2006) 230-232
71. Helbig G., Stella-Holowiecka B., Grosicki S., Bober G., Krawczyk M., Wojnar J., et al. The results of imatinib therapy for patients with primary eosinophilic disorders. Eur J Haematol 76 (2006) 535-536
72. von Bubnoff N., Sandherr M., Schlimok G., Andreesen R., Peschel C., and Duyster J. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 19 (2005) 286-287
73. Baccarani M., Rosti G., de Vivo A., Bonifazi F., Russo D., Martinelli G., et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 99 (2002) 1527-1535
74. Guilhot F., Chastang C., Michallet M., Guerci A., Harousseau J.L., Maloisel F., et al., French Chronic Myeloid Leukemia Study Group. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 337 (1997) 223-229
75. Druker B.J., Guilhot F., O'Brien S., Gathmann I., Kantarjian H., Gattermann N., et al., IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 335 (2006) 2408-2417
76. Frickhofen N., Marker-Hermann E., Reiter A., Walz C., Jung B., Bauer H., et al. Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib. Ann Hematol 83 (2004) 477-480
77. Rose C., Dupire S., Roche-Lestienne C., Grardel N., Bourgeois E., Cambier N., et al. Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft. Leukemia 18 (2004) 354-355
78. Cervetti G., Galimberti S., Carulli G., and Petrini M. Imatinib therapy in hypereosinophilic syndrome: A case of molecular remission. Leuk Res 29 (2005) 1097-1098
79. Score J., Curtis C., Waghorn K., Stalder M., Jotterand M., Grand F.H., et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 20 (2006) 827-832
80. Schaller J.L., and Burkland G.A. Case report: Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med 3 (2001) 9
81. Ault P., Cortes J., Koller C., Kaled E.S., and Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 26 (2002) 881-884
82. Gleich G.J., Leiferman K.M., Pardanani A., Tefferi A., and Butterfield J.H. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359 (2002) 1577-1578
83. ™) induces rapid and complex hematologic remissions in patients with idiopathic hypereosinophilic syndrome (HES) without evidence of BCR-ABL or activating mutations in C-KIT and platelet-derived growth factor receptor-beta (PDGFR- β). Blood 100 (2002) 798a (abstr 3152)
84. Nolasco I., Carvalho S., and Parreira A. Rapid and complete response to imatinib mesylate (STI-571) in a patient with idiopathic hypereosinophilia. Blood 100 (2002) 346b-347b (abstr 4940)
85. Cortes J., Ault P., Koller C., Thomas D., Ferrajoli A., Wierda W., et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 101 (2003) 4714-4716
86. Ishii Y., Ito Y., Kuriyama Y., Tauchi T., and Ohyashiki K. Successful treatment with imatinib mesylate of hypereosinophilic syndrome (chronic eosinophilic leukemia) with myelofibrosis. Leuk Res 28 suppl 1 (2004) 79-80
87. Koury M.J., Newman J.H., and Murray J.J. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib. Am J Med 115 (2003) 587-589
88. Pardanani A., Reeder T.L., Kimlinger T.K., Baek J.Y., Li C.Y., Butterfield J.H., et al. Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk Res 27 (2003) 739-742
89. Salem Z., Zalloua P.A., Chehal A., Bitar N., Abboud M., Kadri A., et al. Effective treatment of hypereosinophilic syndrome with imatinib mesylate. Hematol J 4 (2003) 410-412
90. Malagola M., Martinelli G., Rondoni M., Ottaviani E., Piccaluga P.P., Ricci P., et al. Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: Imatinib mesylate may induce complete molecular and imaging remission. Haematologica 89 (2004) ECR25
91. Martinelli G., Malagola M., Ottaviani E., Rosti G., Trabacchi E., and Baccarani M. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-α positive idiopathic hypereosinophilic syndrome. Haematologica 89 (2004) 236-237
92. Musto P., Falcone A., Sanpaolo G., Bodenizza C., Perla G., Minervini M.M., et al. Heterogeneity of response to imatinib-mesylate (Glivec) in patients with hypereosinophilic syndrome: Implications for dosing and pathogenesis. Leuk Lymphoma 45 (2004) 1219-1222
93. Payne S.M., and Kovacs M.J. Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome. Ann Pharmacother 38 (2004) 1215-1218
94. Pottier P., Planchon B., and Grossi O. [Complete remission with imatinib mesylate (Glivec) of an idiopathic hypereosinophilic syndrome associated with a cutaneous mastocytosis after failure of interferon-alpha]. Rev Med Interne 24 (2003) 542-546
95. Rotoli B., Catalano L., Galderisi M., Luciano L., Pollio G., Guerriero A., et al. Rapid reversion of Loeffler's endocarditis by imatinib in early stage clonal hypereosinophilic syndrome. Leuk Lymphoma 45 (2004) 2503-2507
96. Smith K.J., Jacobson E., Hamza S., and Skelton H. Unexplained hypereosinophilia and the need for cytogenetic and molecular genetic analyses. Arch Dermatol 140 (2004) 584-588
97. Tan D., Hwang W., Ng H.J., Goh Y.T., and Tan P. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: A case report. Int J Hematol 80 (2004) 75-77
98. Wolf D., Gastl G., and Rumpold H. [Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib]. Dtsch Med Wochenschr 129 (2004) 2104-2106
99. Anghel G., De Rosa L., Ruscio C., Petti N., Riccardi M., Severino A., et al. Efficacy of imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome and severe heart involvement. Tumori 91 (2005) 67-70
100. Imashuku S., Kakazu N., Ueda I., Morimoto A., Harada H., Teramura T., et al. Response to imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome associated with cyclic eosinophil oscillations. Int J Hematol 81 (2005) 310-314
101. Müller A.M., Martens U.M., Hofmann S.C., Bruckner-Tuderman L., Mertelsmann R., and Lubbert M. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: Two case reports and a comprehensive review of the literature. Ann Hematol 85 (2006) 1-16
102. Musial J., Brzezinska-Kolarz B., Sanak M., and Szczeklik A. Improved cardiac function in a patient with hypereosinophilic syndrome treated with imatinib. Eur J Haematol 75 (2005) 87-88
103. Onitilo A.A., Kio E.A., Singh A.K., and Lazarchick J. Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction. Leuk Lymphoma 46 (2005) 1667-1670